0
Skip to Content
WindroseCG
WindroseCG
OUR SERVICES
WHY WINDROSE
INSIGHTS
OUR TEAM
CAREERS
Contact
WindroseCG
WindroseCG
OUR SERVICES
WHY WINDROSE
INSIGHTS
OUR TEAM
CAREERS
Contact
OUR SERVICES
WHY WINDROSE
INSIGHTS
OUR TEAM
CAREERS
Contact

 

CMS’s Cell and Gene Therapy (CGT) Access Model: Implications of Outcome-based Payment Models for Pharmaceuticals
Articles Adam Foster 2024-07-03 Articles Adam Foster 2024-07-03

CMS’s Cell and Gene Therapy (CGT) Access Model: Implications of Outcome-based Payment Models for Pharmaceuticals

The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder.

Read More
Medicare’s Aduhelm NCD Has Implication Outside of Alzheimer’s Disease
Articles Adam Foster 2022-02-11 Articles Adam Foster 2022-02-11

Medicare’s Aduhelm NCD Has Implication Outside of Alzheimer’s Disease

As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).

Read More
 

PHILADELPHIA OFFICE

161 Washington Street, Suite 330 Conshohocken, PA 19428

Phone: (484) 235-0599
info@windrosecg.com

LONDON OFFICE

69 Carter Lane
London, EC4V 5EQ

Phone: +44 (0) 203-621-4171
info@windrosecg.com

SWITZERLAND OFFICE

Grabenstrasse 8,
6004 Lucerne

info@windrosecg.com

Contact us

Privacy Policy

Inclusion and Diversity Policy

© 2024 Windrose Consulting Group